While the malaria death count in Cambodia dropped to just one case in 2016, a new threat to the race against the disease arises in south-eastern Asia: superbugs. A superbug is a drug-resistant, human-killing parasite that modern medicine struggles to combat.
BASF scientist, Matthias Witschel, is seeking new ways to combat malaria. A 19th century dyestuff is playing an important role.
Our CTO and Co-founder David Mendels answers our most commonly asked question.
Why not let MalariaWorld play a vital role in supporting ground breaking studies that often lack the preliminary ecological field data, required by traditional funders?
We, as dedicated scientists, can assemble a global bank of preliminary scientific field data for “high risk” project proposals to open new directions within malaria research. In doing so, young scientists are able to test creative ideas ahead of time and more experienced scientists are able to explore unexpected and promising observations or discoveries.
This evaluation addresses drug usage, safety concerns following early exposure, implications for changed pharmacokinetics and reduced parasite susceptibility. Clinical-use updates and strategies to address some knowledge gaps including key operational research are discussed.
The results show that a sample of field-caught An. plumbeus has a moderate to high receptivity towards P. falciparum.
In this position paper, the European Society for Clinical Microbiology and Infectious Diseases, Study Group on Clinical Parasitology, summarizes main issues regarding the management of imported malaria cases.
This study highlights the heterogeneity of standards of care within Europe.
The Tropical Institute and Max von Pettenkofer – Institute of the University of Munich offer a PhD position for at least 3 years for their Malaria Projects in Munich and Africa.
Deadline for applications: 14 November 2011
Multicenter trials in Southeast Asia have shown better survival rates among patients with severe malaria, particularly those with high parasitemia levels, treated with intravenous (IV) artesunate than among those treated with quinine.